Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 1
2005 3
2008 3
2009 8
2010 3
2011 3
2012 5
2013 4
2014 7
2015 3
2016 4
2017 2
2018 2
2019 4
2020 1
2021 6
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Checkpoint inhibition in hematologic malignancies.
Tsumura A, Levis D, Tuscano JM. Tsumura A, et al. Among authors: tuscano jm. Front Oncol. 2023 Oct 17;13:1288172. doi: 10.3389/fonc.2023.1288172. eCollection 2023. Front Oncol. 2023. PMID: 37920162 Free PMC article. Review.
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma.
Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL. Chavez JC, et al. Among authors: tuscano jm. Clin Cancer Res. 2023 May 15;29(10):1869-1878. doi: 10.1158/1078-0432.CCR-22-2955. Clin Cancer Res. 2023. PMID: 36826995 Free PMC article.
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
Othman T, Moskoff BN, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Othman T, et al. Among authors: tuscano jm. Leuk Res. 2022 Aug;119:106885. doi: 10.1016/j.leukres.2022.106885. Epub 2022 Jun 8. Leuk Res. 2022. PMID: 35738024 Free article.
Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.
Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E. Tuscano JM, et al. Clin Cancer Res. 2021 Sep 1;27(17):4726-4736. doi: 10.1158/1078-0432.CCR-20-4622. Epub 2021 Jun 4. Clin Cancer Res. 2021. PMID: 34088724 Free PMC article.
64 results